The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
BaseLaunch has supported 27 biotech companies across multiple modalities and indications
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Therapy recently approved in Canada under the brand name KORSUVA
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Acute therapies continue to report strong growth compared to chronic ones.
The state-of-the-art facility provides a pathway from development to large-scale biologics production
Subscribe To Our Newsletter & Stay Updated
